J
Jonathan A. Fletcher
Researcher at Brigham and Women's Hospital
Publications - 426
Citations - 57627
Jonathan A. Fletcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: GiST & PDGFRA. The author has an hindex of 109, co-authored 413 publications receiving 53642 citations. Previous affiliations of Jonathan A. Fletcher include Albany Medical College & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain
Susanne Grunewald,Lillian R. Klug,Thomas Mühlenberg,Jonas Lategahn,Johanna Falkenhorst,Ajia Town,Christiane Ehrt,Eva Wardelmann,Wolfgang Hartmann,Hans Ulrich Schildhaus,Juergen Treckmann,Jonathan A. Fletcher,Sascha Jung,Paul Czodrowski,Stephen D. Miller,Oleg Schmidt-Kittler,Daniel Rauh,Michael Heinrich,Sebastian Bauer +18 more
TL;DR: Tumor and plasma biopsies in 6 of 7 patients with PDGFRA primary mutations who progressed on avapritinib or imatinib had secondary resistance mutations withinPDGFRA exons 13, 14 and 15 that interfere with avapriteinib binding.
Journal ArticleDOI
ALK-rearranged renal cell carcinomas in children
Mariana M. Cajaiba,Lawrence J. Jennings,Stephen Rohan,Antonio R. Perez-Atayde,Adrián Mariño-Enríquez,Jonathan A. Fletcher,James I. Geller,Katrin M. Leuer,Julia A. Bridge,Elizabeth J. Perlman +9 more
TL;DR: Based on the shared unique morphologic, immunophenotypic, and genetic features, it was proposed that these neoplasms belonged to a distinct subgroup of RCC frequently occurring in pediatric patients, which they have termed as ALK‐rearranged RCC.
Journal ArticleDOI
Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Inga-Marie Schaefer,Jonathan A. Fletcher,G. Petur Nielsen,Angela R. Shih,Marco Ferrone,Jason L. Hornick,Xiaohua Qian +6 more
TL;DR: The objective of the current study was to validate H3G34W and H3K36M IHC in the diagnosis of giant cell‐rich bone tumors on fine‐needle aspiration and core needle biopsy specimens.
Journal ArticleDOI
Cytologic and fluorescence in situ hybridization (FISH) examination of metanephric adenoma
TL;DR: The differential diagnosis includes Wilms' tumor, renal adenoma, papillary renal cell carcinoma, and metastatic tumors, and both immunohistochemistry and FISH may be of help in distinguishing some of these lesions.
Journal ArticleDOI
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
Grant Eilers,Jeffrey T. Czaplinski,Mark Mayeda,Nacef Bahri,Derrick Tao,Meijun Zhu,Jason L. Hornick,Neal I. Lindeman,Ewa Sicinska,Andrew J. Wagner,Jonathan A. Fletcher,Adrián Mariño-Enríquez +11 more
TL;DR: CDK4/6 inhibition is a preclinically effective treatment against p16-negative, imatinib-resistant FS-DFSP, and should be evaluated as a therapeutic strategy in patients with unresectable or metastatic imatinIB-resistant DFSP.